ASH Clinical News December 2014 | Page 25

The ClonoSIGHT Process: ™ Reveal deeper MRD Ultra-sensitive sequencing-based MRD assessment for lymphoid cancers Universal, standardized assay Specimen flexibility Secure online results portal Learn more at clonosight.com Visit us at the 56th ASH Annual Meeting Booth #1243